MarketCap
Facebook
X
TelegramAnnual report 2023
added 03-22-2024
Recro Pharma Operating Income 2011-2026 | REPH
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Recro Pharma
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -3.57 M | 279 K | 412 K | -8.34 M | 23.6 M | 12.5 M | -40.3 M | -25.8 M | -6.97 M | -11.9 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 23.6 M | -40.3 M | -6 M |
Quarterly Operating Income Recro Pharma
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.76 M | -968 K | -2.6 M | - | 215 K | 302 K | -851 K | - | 336 K | 1.84 M | -2.86 M | - | 2.48 M | -1.02 M | -2.57 M | - | 9.43 M | 9.94 M | 3.79 M | - | -13.6 M | -13.3 M | -12.8 M | - | -10.7 M | -9.43 M | -7.3 M | - | -3.92 M | -6.77 M | -5.02 M | - | -164 K | 373 K | -4.14 M | - | -4.72 M | -2.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 9.94 M | -13.6 M | -2.71 M |
Operating Income of other stocks in the Drug manufacturers industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
-13.5 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Agile Therapeutics
AGRX
|
-19.9 M | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-25.1 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-46.4 M | - | - | $ 754 M | USA |
 |
Catalent
CTLT
|
-749 M | - | - | $ 11.5 B | USA |
 |
Eagle Pharmaceuticals
EGRX
|
81 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
-469 M | - | - | $ 28.9 M |  Irlanda |
 |
DURECT Corporation
DRRX
|
-36.9 M | - | - | $ 50.1 M | USA |
 |
Alimera Sciences
ALIM
|
-1.93 M | - | - | $ 142 M | USA |
 |
Athenex
ATNX
|
-70 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-42.4 M | - | - | $ 2.06 B |  France |
 |
Evoke Pharma
EVOK
|
-7.43 M | - | - | $ 36.6 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
-1.84 M | $ 3.23 | 3.53 % | $ 45.4 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-524 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-85.5 M | - | 2.45 % | $ 38.1 M |  Canada |
 |
Sundial Growers
SNDL
|
-132 M | $ 1.4 | 1.82 % | $ 3.37 M | Canada |
 |
Bausch Health Companies
BHC
|
963 M | $ 5.76 | 0.7 % | $ 2.1 B | Canada |
 |
Tilray
TLRY
|
-1.37 B | $ 6.94 | 3.2 % | $ 4.29 B | Canada |
 |
Harrow Health
HROW
|
30.5 M | $ 38.63 | 4.12 % | $ 1.42 B | USA |
 |
Aurora Cannabis
ACB
|
-283 M | $ 3.55 | 1.88 % | $ 86.3 M | Canada |
 |
Canopy Growth Corporation
CGC
|
-117 M | $ 1.08 | - | $ 116 M | Canada |
 |
Veru
VERU
|
-36.9 M | $ 2.41 | 1.26 % | $ 325 M | USA |
 |
OrganiGram Holdings
OGI
|
-91.8 M | $ 1.45 | 2.19 % | $ 402 M | Canada |
 |
Viatris
VTRS
|
766 M | $ 13.99 | 1.12 % | $ 16.8 B | USA |
 |
Lannett Company
LCI
|
-176 M | - | 1.15 % | $ 7.11 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-103 M | - | - | $ 193 M | Canada |
 |
Evolus
EOLS
|
-32.7 M | $ 4.39 | 1.27 % | $ 283 M | USA |
 |
Emergent BioSolutions
EBS
|
-726 M | $ 8.82 | 6.98 % | $ 452 M | USA |
 |
Organogenesis Holdings
ORGO
|
-1.28 M | $ 2.48 | 3.99 % | $ 327 M | USA |
 |
Pacira BioSciences
PCRX
|
-73.4 M | $ 24.08 | 0.06 % | $ 1.11 B | USA |
 |
PetIQ
PETQ
|
37.1 M | - | 1.64 % | $ 400 M | USA |
 |
ProPhase Labs
PRPH
|
23.6 M | - | - | $ 5.07 M | USA |
 |
Relmada Therapeutics
RLMD
|
-59.1 M | $ 7.48 | 1.36 % | $ 295 M | USA |
 |
Assertio Holdings
ASRT
|
-21.5 M | $ 18.03 | 0.03 % | $ 115 M | USA |
 |
Radius Health
RDUS
|
-54.3 M | - | - | $ 1.42 B | USA |
 |
cbdMD
YCBD
|
-3.32 M | $ 0.73 | -2.0 % | $ 3.15 M | USA |
 |
OptiNose
OPTN
|
-22.7 M | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
-16.1 M | $ 1.05 | 3.47 % | $ 52.4 M | USA |
 |
PLx Pharma
PLXP
|
-40.8 M | - | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
-179 M | $ 8.68 | 3.46 % | $ 760 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-3.71 M | $ 2.44 | 3.62 % | $ 3.03 M | USA |
 |
Zomedica Corp.
ZOM
|
-84.4 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-35.3 M | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
-4.69 M | $ 0.92 | -2.1 % | $ 33.1 M | USA |
 |
Tricida
TCDA
|
-153 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
-3.24 M | $ 0.63 | -3.05 % | $ 2.7 M |  China |
 |
TherapeuticsMD
TXMD
|
-4.39 M | $ 2.15 | 5.12 % | $ 24.9 M | USA |